Physician profile
Rommel Go
NPI 1477548469
$15,653.45
in general payments reported to CMS, 2019-2025
67 companies · $910 in 2025
The $910 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,643 · 2020: $2,533 · 2021: $2,994 · 2022: $2,938 · 2023: $2,296 · 2024: $1,340 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,544.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,793.47 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,254.17 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,089.72 | 2019-2025 | Relistor, Xifaxan |
| Amgen INC. | $1,019.09 | 2019-2024 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $971.87 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $908.53 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $581.86 | 2019-2023 | |
| Allergan, INC. | $509.02 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $503.77 | 2019-2025 | Verquvo, Belsomra |
| Pfizer INC. | $491.57 | 2019-2023 | |
| Lilly USA, LLC | $466.64 | 2019-2024 | Mounjaro |
| Indivior INC. | $433.13 | 2019-2025 | Sublocade |
| Amarin Pharma, INC. | $422.10 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $363.27 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $345.57 | 2020-2023 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rommel Go listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.